Evidence-based expert consensus on clinical management of safety of Bruton's tyrosine kinase inhibitors (2024).

• DOI: 10.21147/j.issn.1000-9604.2024.03.02
• Publication Date: 2024-06-30
• Authors: Zaiwei Song; Dan Jiang; Lingling Yu; Yixuan Chen; Daobin Zhou; Yue Li; Depei Wu; Lingli Zhang; Liyan Miao; Jun Ma; Jun Zhu; Hongmei Jing; Rongsheng Zhao; On Behalf Of The ...; NULL AUTHOR_ID; Hospital Pharmacy...; Division Of Thera...; Expert Committee ...; Expert Committee ...; Society Of Integr...; Chinese Society O...; Hospital Pharmacy...

Bruton's tyrosine kinase inhibitors (BTKis) have revolutionized the treatment of B-cell lymphomas. However, safety issues related to use BTKis may hinder continuity and further affect clinical efficacy. A comprehensive systematic expert consensus from a pharmacological perspective is lacking for associated with BTKi treatment. multidisciplinary working group was established, comprising 35 members fields hematology, cardiovascular disease, cardio-oncology, pharmacy, evidence-based medicine. This formulated using an approach Delphi method. The Joanna Briggs Institute Critical Appraisal (JBI) tool Grading Recommendations Assessment, Development, Evaluation (GRADE) were used rate quality evidence grade strength recommendations, respectively. provides practical recommendations medication based on nine aspects within three domains, including management common adverse drug events such as bleeding, events, hematological toxicity, well drug-drug interactions guidance special populations. could contribute promoting multi-dimensional, standardized BTKis.